<DOC>
	<DOC>NCT01815541</DOC>
	<brief_summary>This is a biomedical research, prospective, mono centric, tolerance study Of the administration of subcutaneous teicoplanin in the treatment of osteoarticular infections.</brief_summary>
	<brief_title>Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>Patient over 18 years Inpatient orthopedic surgery Achieved a bone and joint infection documented gram + (staphylococci golden coagulasenegative staphylococci, enterococci, streptococci) Bacteria resistant to lincosamides, quinolones and rifampicin Bacteria susceptible to teicoplanin (MIC â‰¤ 4 mg / L) Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL) Patient not affiliated to the social security Pregnant and lactating women Known hypersensitivity to teicoplanin (rash, ...) Patients with a central catheter or an implantable chamber Patient hemodialysis Patient has another participant biomedical research on a drug to prevent drug interactions Patient minor Patient major protected (protection of the court, wardship, trusteeship) Patient admitted for emergency or incapable of consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>subcutaneous teicoplanin</keyword>
	<keyword>osteoarticular</keyword>
	<keyword>infections</keyword>
	<keyword>tolerance</keyword>
	<keyword>teicoplanin</keyword>
</DOC>